• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症患者药物治疗依从性差的风险因素:基于电子病历的疾病修正治疗使用的解释模型的建立。

Risk Factors for Suboptimal Medication Adherence in Persons With Multiple Sclerosis: Development of an Electronic Health Record-Based Explanatory Model for Disease-Modifying Therapy Use.

机构信息

Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, Connecticut; Psychology Service, VA Connecticut Healthcare System, West Haven, Connecticut; Department of Neurology, University of Connecticut School of Medicine, Farmington, Connecticut; Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, Connecticut; Department of Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, Connecticut.

Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, Washington; Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, Washington; Department of Rehabilitation Medicine, University of Washington, Seattle, Washington.

出版信息

Arch Phys Med Rehabil. 2020 May;101(5):807-814. doi: 10.1016/j.apmr.2019.11.005. Epub 2019 Dec 3.

DOI:10.1016/j.apmr.2019.11.005
PMID:31809751
Abstract

OBJECTIVE

To determine which factors are associated with suboptimal disease-modifying therapy (DMT) adherence and to develop an explanatory model that could be used to identify individuals at risk and potentially inform interventions.

DESIGN

Cross-sectional cohort study using electronic health records.

SETTING

Veterans Health Administration (VA).

PARTICIPANTS

Veterans with multiple sclerosis (MS) (N=2939; 79.69% men) who received care through the VA and were included in the VA MS Center of Excellence Data Repository.

INTERVENTIONS

Not applicable.

MAIN OUTCOME MEASURES

Suboptimal DMT adherence (<80%), demographics, co-occurring conditions, and health care use.

RESULTS

Nearly 31% of participants had suboptimal adherence. Flags for suboptimal adherence included >20% missed appointments (odds ratio [OR], 3.78; 95% CI, 2.45-2.82), traumatic brain injuries (OR, 1.55; 95% CI, 1.12-2.14), age younger than 59 years (OR, 1.47; 95% CI, 1.23-1.74), ≥1 emergency department visits (OR, 1.40; 95% CI, 1.18-1.67), mood disorders (ie, depressive and bipolar disorders) (OR, 1.40; 95% CI, 1.18-1.66), and service connection (OR, 1.22; 95% CI, 1.01-1.47). Hyperlipidemia (OR, 0.77; 95% CI, 0.65-0.92) and being issued a wheelchair (OR, 0.83; 95% CI, 0.70-1.00) were associated with lower risk.

CONCLUSIONS

Suboptimal adherence to DMTs continues to be an issue. Interventions that focus on person-level barriers should be urgently explored to increase adherence and improve self-management abilities.

摘要

目的

确定哪些因素与疾病修正治疗(DMT)依从性不理想相关,并建立一个解释模型,以识别有风险的个体,并可能为干预措施提供信息。

设计

使用电子健康记录的横断面队列研究。

地点

退伍军人事务部(VA)。

参与者

接受 VA 医疗服务并被纳入 VA 多发性硬化症卓越中心数据存储库的 2939 名多发性硬化症(MS)退伍军人(79.69%为男性)。

干预措施

不适用。

主要观察指标

DMT 依从性不理想(<80%)、人口统计学、共病和医疗保健使用情况。

结果

近 31%的参与者依从性不理想。依从性不理想的标志包括:错过预约>20%(比值比[OR],3.78;95%置信区间[CI],2.45-2.82)、创伤性脑损伤(OR,1.55;95%CI,1.12-2.14)、年龄<59 岁(OR,1.47;95%CI,1.23-1.74)、≥1 次急诊就诊(OR,1.40;95%CI,1.18-1.67)、心境障碍(即抑郁和双相情感障碍)(OR,1.40;95%CI,1.18-1.66)和服务连接(OR,1.22;95%CI,1.01-1.47)。高血脂症(OR,0.77;95%CI,0.65-0.92)和发放轮椅(OR,0.83;95%CI,0.70-1.00)与较低的风险相关。

结论

DMT 依从性不理想仍然是一个问题。应紧急探索以个人为中心的障碍为重点的干预措施,以提高依从性并改善自我管理能力。

相似文献

1
Risk Factors for Suboptimal Medication Adherence in Persons With Multiple Sclerosis: Development of an Electronic Health Record-Based Explanatory Model for Disease-Modifying Therapy Use.多发性硬化症患者药物治疗依从性差的风险因素:基于电子病历的疾病修正治疗使用的解释模型的建立。
Arch Phys Med Rehabil. 2020 May;101(5):807-814. doi: 10.1016/j.apmr.2019.11.005. Epub 2019 Dec 3.
2
Who is not coming to clinic? A predictive model of excessive missed appointments in persons with multiple sclerosis.谁不来诊所?多发性硬化症患者过度失约的预测模型。
Mult Scler Relat Disord. 2020 Feb;38:101513. doi: 10.1016/j.msard.2019.101513. Epub 2019 Nov 9.
3
Demographic and Clinical Factors Are Associated With Frequent Short-Notice Cancellations in Veterans With Multiple Sclerosis on Disease Modifying Therapies.人口统计学和临床因素与接受疾病修正治疗的多发性硬化症退伍军人频繁的临时取消预约有关。
Arch Phys Med Rehabil. 2022 May;103(5):915-920.e1. doi: 10.1016/j.apmr.2021.10.004. Epub 2021 Oct 22.
4
Neuropsychological assessments and psychotherapeutic services in Veterans with multiple sclerosis: Rates of utilization and their associations with socio-demographics and clinical characteristics using Veterans Health Administration-based data.多发性硬化症退伍军人的神经心理学评估和心理治疗服务:基于退伍军人健康管理局数据的利用率及其与社会人口统计学和临床特征的关联
Mult Scler Relat Disord. 2020 Aug;43:102220. doi: 10.1016/j.msard.2020.102220. Epub 2020 May 26.
5
Adherence to Disease-Modifying Therapies for Multiple Sclerosis.多发性硬化症的疾病修正疗法的依从性。
J Manag Care Spec Pharm. 2016 Dec;22(12):1394-1401. doi: 10.18553/jmcp.2016.22.12.1394.
6
Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.多发性硬化症药物治疗的依从性和持续性:一项基于人群的研究。
Mult Scler Relat Disord. 2016 Jul;8:78-85. doi: 10.1016/j.msard.2016.05.006. Epub 2016 May 7.
7
The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.在美国,坚持治疗对多发性硬化症患者住院和急诊就诊的影响。
J Med Econ. 2016;19(5):497-505. doi: 10.3111/13696998.2015.1134546. Epub 2016 Jan 18.
8
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.多发性硬化症中疾病修正疗法不依从性的决定因素:一项全加拿大前瞻性研究。
Mult Scler. 2017 Apr;23(4):588-596. doi: 10.1177/1352458516657440. Epub 2016 Jul 11.
9
Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.一组约旦复发缓解型多发性硬化症患者对疾病修饰疗法的药物依从性:一项多中心横断面研究。
Int J Pharm Pract. 2023 Apr 10;31(2):198-205. doi: 10.1093/ijpp/riac081.
10
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.与其他改善病情疗法相比,芬戈莫德治疗多发性硬化症的持续用药和依从性:一项美国索赔数据库回顾性分析
J Med Econ. 2014 Oct;17(10):696-707. doi: 10.3111/13696998.2014.940422. Epub 2014 Jul 23.

引用本文的文献

1
Understanding Depression in People Living with Multiple Sclerosis: A Narrative Review of Recent Literature.了解多发性硬化症患者的抑郁症:近期文献的叙述性综述
Neurol Ther. 2025 Jun;14(3):681-710. doi: 10.1007/s40120-025-00728-8. Epub 2025 Mar 27.
2
Treatment satisfaction with disease-modifying therapy is the only predictor of Adherence among multiple sclerosis patients from Upper Egypt.治疗满意度是改善多发性硬化症患者治疗依从性的唯一预测因素,本研究来自埃及上埃及地区。
Sci Rep. 2024 Mar 25;14(1):7027. doi: 10.1038/s41598-024-57116-9.
3
Preferences and Perspectives of Specialist Multiple Sclerosis Nurses and Patients with Multiple Sclerosis Regarding the New RebiSmart 3.0 Autoinjector versus Other Assistive Devices.
多发性硬化专科护士和多发性硬化患者对新型RebiSmart 3.0自动注射器与其他辅助设备的偏好和看法。
Med Devices (Auckl). 2024 Feb 19;17:59-71. doi: 10.2147/MDER.S438883. eCollection 2024.
4
Effect of an educational intervention based on the theory of planned behavior on improving medication adherence in patients with multiple sclerosis treated with injectable disease-modifying drugs: randomized controlled trial.基于计划行为理论的教育干预对改善多发性硬化症患者使用注射用疾病修正药物的药物依从性的效果:随机对照试验。
BMC Public Health. 2023 May 30;23(1):999. doi: 10.1186/s12889-023-15910-6.
5
Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis.多发性硬化症中疾病修饰疗法依从性和持续性的预测因素。
Ther Adv Neurol Disord. 2021 Oct 5;14:17562864211031099. doi: 10.1177/17562864211031099. eCollection 2021.
6
The Multiple Sclerosis Centers of Excellence: A Model of Excellence in the VA.卓越多发性硬化症中心:退伍军人事务部的卓越典范。
Fed Pract. 2020 Apr;37(Suppl 1):S6-S10.